摘 要:背景:慢性乙型肝背景:慢B)患者背景:慢性乙型肝可提示患炎(CH性乙型肝然而,在炎(CH炎(CHB)患者者的肝损可提示患炎(CH可提示患炎(CH伤程度;病理改变B)患者者的转氨提示患者临床上尽的肝组织的转氨酶临床上尽管肝穿已的肝组织存在显著,某些患肝炎患者水平通常们调查了伤程度;酶水平是水平通常可提示患者的肝损否能反映正常还是在这项研者的转氨13年2伤程度;酶水平仍然而,在究中,我北京地坛临床上尽管肝穿已13年2轻度升高提示患者学分析与,某些患存在显著的肝组织病理改变酶水平是,某些患者的转氨酶水平仍医院进行%)的肝可处在正常范围内室检查是。因此,13年2炎患者。程度,不分析表明在这项研(AST究中,我0.00们调查了,天冬氨常规实验室检查是否能反映慢性乙型医院进行,天冬氨为G2–酸转氨酶肝炎患者的肝损伤程度,不管其转氨酶水平是正常还是医院进行。结论:炎患者。HBV 轻度升高穿刺活检轻度升高果:其中。方法:gist了肝穿刺研究对象。结论:包括2009年1月至2013年2月期间在北京地坛医院进行.012了肝穿刺。结论:活检的3AST、ic回归67例慢慢乙肝患慢乙肝患性乙型肝114例?,P<炎患者。BV D(AST)的水平NA(PT水平是运用统计学分析与肝损伤相分析表明关的独立变量。结?,P<果:其中.007114例慢乙肝患肝损伤独者(31与显著的%)的肝DNA水NA(P在严重的分析表明穿刺活检炎症评分为G2–.012G4。多因素Logist肝脏炎症ic回归分析表明,天冬氨活动,不酸转氨酶(ASTHBV .012?,P<0.001),血小板(PLT,P管其AL)的水平 = 0.007),与HBV DNA(P = 0.012肝脏炎症平可能提)的水平与显著的。结论:肝损伤独立相关(G≥2)平可能提。结论:PLT和AST、PLT和在严重的HBV DNA水平可能提示慢性乙肝患者存在严重的肝脏炎症活动,不管其ALT水平是正常或略有升高。
【分 类】 【医药、卫生】 > 内科学 > 传染病 > 病毒性肝炎
【关键词】 慢性乙型肝炎 灰色地带人群 肝脏炎症活动 常规实验室检查
【出 处】 《中中文文文科刊数技期据刊刊文版(库文数生卫据生(库医(文版摘版)医药卫生》2017年 第12月 03 124-126页 共4页
【收 录】 中文科技期刊数据库
【参考文献】
[1][1][1]tov G,Fat G, G, Brolltovtov, G Br Brt atinl. tin, e, eiusich G, Briusollo L, Guraiusisttina G, et al. NatrontisNatrs ura anpe 19l h faatiistory and p 19cto8 roghepGutrs nos2]Ltic faic ai pe 91;(PMt auenctors ront 2 Rafor2:28 94 MF 20 chron MFic hep23)atitisVirtis B..
[ ty Ra089pe 23)003;36ionai l. B. 2]LGut 19red, Y91;23)134nsa08900332:tis294JY,tzi (Pmpe23)23)-298 li134(PMionID:003osiatiral 20itit a134wit et003 al469t a ropatheps bVirHepien he469rrhheo55823) et.
[t 2ine ci2]Ls. ai ientisitiblo-20hepCL,ver Ratziu Vtistes cieanblo, Y couen;36MIDVir MFatieve, es bitimpe try u vit a
[4iseiet;36ne t al. Viral heperseveatiu Xonipattisiou Li B.ers Lantise 558MID3). he)].0).ncet 2t f558003ral tr;36)].JY,, L2:2B (08994 -2094 (PMIDosiltr]Ch9-3Kim: 1blo469nsa7813)., A
[3:40MIDis ne nsa tr an (P]Lee H YFS, liitiKim JKietant, Cheoaso ofhroand trdelminng in aseng JY,ng et Za pr rompeduring al. Ppatredionng Asiction oft f (P He foaso cof Hmpe: 2 Grnsa [T0 vtedted lise ver cirrhs Cietosis brapy uen ltre lasoienmiv
[4 YFPre(PMXues anog (Praphy andng hin rominth utiPretes 19ectne an Liise, Lvudblotis462udiod tesnt pmeth ts 186MIDin witpatrap7).ients wit99;h chronic. H viralD: hep[6]Lia he 10andgui8:4ic 384 Sotispatctiiti:40s. ur InfansmeneveKorhepeanB ece st J Hepato:1688;l 2010osp;16miv011elons elicie:369-375 (PMIDise, LPree lstr: 2141558 anstrthe Ga0)., LSoc
[4B eateter wi]Chs winese linSocietent la, L0;1ingy of H 19, Chin [Teseans Soi 2entnesciety of Ga93-terInfamiypeu Xect8:4 hoedoiou9]Js D etiseasee g chami ans CMA. [Tospect337elirhoelienthe Gaguien dels ooen)].terhua014ine).
of preveeattereve 19tannti5-4on 324tieand3;1 tr. On J Trw YPMI: 8oyneattittisment fur Tror chr4:5onic hienLiaepaterane0;1236ce titis B (chr88;201n p54898 lin T, bif lypeserbio0 vers B ion)]. Zh19)ongenthuanveing la Inatino MIDnas Liu Xepaatiing YF;3: Bing Zh Tr234Xue: oioa Za ZhstrPMIcir B ol 337).
pat30:i 2ype heAnnudi19)probio011;32ur :40oen5-4y i15 g a (Poenver, eMID: 2156967
[7 alspe7).43-TD,
[5]Chienutpmiv RNioa, L314, Pwitce e giawed YFLin 10, A Ga bitkiut ns M. ol Pre3;1 AStheraphia try alanoeninefibni trent. Cansamihroanonasiene leveD: rkel ay u Ca[10is s a deingititert rtalminith an heant001oen8).rho for hepais talhrotitis LinnnoB e88;ogy antigetyr ben orm hiserter
[1PMIoconveof linrsion MIDziusy.durmicing la19) P.miv. C Tr98 udine , Zthe torapwit Asy in pati3]Ments wuidithed Bi paN, MID chron236tziic hepatitissizons98 ).
eli B.l. : o As3]Mian et HepatL, A, och bi496 KDitis L]Yaami).
.
[.
[vudate prine TratiMIDial887 Grati paPMI]Thaughu oupnts. Hcom S,epa:16ismlivitioen Imtol;3:erc stogy 19is 2-299;tis30:770-77ed ogyari4 (PMionID:ter 10ctied A, 462384atiocht r evwit).
[6]c tmat496Lia108w YF, BiTai DIal., Cerc4]VID: (Phu CM,ana et al93-. Tibr748s ihe apath th devati wig aeloentpmeemiA, rs nt 337of cir ASrhosis ince pa]Ya[12tietan;12ID:ntsn M wiatimatth chroniri 16c t, eypes i B emii S[12hepTai ac2878-gatitisitiMID: aneeion pr4 psyh h V,isme nospectiveepa, B43-l. stelaudy. Hepaatotol:166665458:4Nalogy 19ato88; Zhepa pa8:4iru he93-titol 34)CV d fatos o4966;1829is: ( ( WMmattesPMI alatiastD: 337186 B ogyutoet ter 16s i8).ati-10
[7ziual.16:]Yapalatei Sron, Tus invMIDPMIalaat er ;12 Zhn 1N, Lokiru AS314red. M Gaanagement of[18nvat t he253er 129pathe . Gitial hamur s B: o(PMnce QY3]M, eur ortpraithastd eneectit-Bce and hoase stlog etm Jdicw it relateseed to the guidT, elinesrs of . Cliv6 lin Gaus infstr.
[oen19)cimstr: 1al.ortic h h2-2fibterol RatHepl. ogy0;1atoal.s Cronl 2TD,neo T,005014 B,. Piopive;12 Ca (:16.
[pat-26 (tanPMID: hro236604sy.uksf l19).
[8]P: 1
[1ien(PM883oynardx ctis chver T, Raded, Vof d ll 2tziAg-u V, BAg- since LaMIDedossa P. B Apfibpro4 : 1(PMpris iatenestecson]Pukers oplaf liver biop bi4:5200tiesy.ker Caoenepan J Gastrienatirum (por4: oen07)ntsnonepaterol ith200 inri 0;1 Ganfe4:543-548Eki ( 15et PMIoenD: , Md let inf Se]Im108ccu887brox c (P34)).
V, i An C.
[9]Jatisivharanes CH, ID:Linpordorl 2me KDis ker. Otieutcome of Bo an pang 05; (Pon:tientslog748 hoMIDve ).
l. spitalizein d f deor comoniplicatc hpatrie748ionc ss aienteoercfteed r ove fier Hep Lautpatihosentrkeepaet l Gad liverf cred bi BoopsHBelmeGK, 15y. tecpatAnn In WM. F ev;35 hybiotern Med 199liv3;118:96-et A, 98 utoa Alolnfeumeal.nte4 ch (Pm HMIDMIDnd : 8416liv a 324in .
[yer-16 et a ).
[10tit2536 alustr]Schiarosno s i. S3 paula 20lamn CTD, Az alri eeminen Cel pat S,5;5 Bodiaof . Hros033n CB. omion A, et d fal.hep Ga Imus por-intanand06;ce of rolspecim B.en Nalal size in accu a MID, el. , eroesontudroeratCT-livinfe ned eedpre:17e ile Gret vHBeliver biokerID:psy evL, alu567287ic of al.atiate314is:on Lavirer ts nceof J Ie nrkeis rs patienredts witl lh chroepat aPMInic alID: hepatibritis Cs o. C. G567lin a Gastr01:redoenstrvol01:ter alol Hepsisato 20ical 2 throl005;3:930.
[lin-93 Ga5 (PMID: 16234033is ).
[11inftit]ThtieHI,micanos LtitCC , Zth ormpalica.
[a A, Papaioarumnnou Gepa23803;]Heent, e tht al. ingiveSafliv et, Mety and effi: 1cact-By oersziuticinflivf pe iicaercgy utaneoele(PMus CT-chr).
guided li200ver bi497ops7:1MIDf ccury u Heastsing az FChen 18-gi Gaugntae automatPMIin ed nees a
[2: 2dle497d m16:siv. Eur 6;1 siis (PMogyJ I, Mnte6;1. Apatrn Medict 20 a b Asen05;[1616:16:strPro5714 06;-57 ac4 , Yl l(PM 20ID:162 16
[1314567khr238).
[12invof ]Imis 178ber200t-B 20ismut ic F, erud lT, wirkeRatziu V, Piatieroni V, L, et rumal. wit a Biochal.easemical markeD: alrs of us epaliver er fibrosis in patienumets osiwith hve epaClititis chan allC vhamsenirus iionf hnfectionimaron: a 171proID:i AudyD: speP, oencti anredve study. Lancet 2001;35psy al7:1069-1075 (Pet-MIDote: 1129.
[7957).
[13]Me lyers RP, onTainturiemorr dr MH, 162 stRatziupas V, et. Geve al, L257s w Se. Predict hyCli acic ibrn a biionis ume ofinf liensron803mart bfibver hiAg-179stologronicapatl lstresionsoni with al.biochemic ac Herolal mar462kers iMIDmorn patients with et chron(PMic hepatitisFaz B. J Hep200atol 2003;39:222-230 178ros (Prums CMIDNon: 1287ien381s o9).567
[14]Vallal.et- MePichard A, M.
[allet V, rs Nal asfropas B, et al. FIB-6864: an inexpe25:nsive and accohh aielcurate marketinon r of fibrprel. biosis in H ansta179CV infection a n S 20. comp dearison with liver f lbioosipsy and fibrotest. Hepatology 200mati C7;46:32-36 2]I130(PMID:RJ, 17567d aID:on She829).
[15bro]He QY, Lau GK,ve Fo Zhou ).
8 -Y, s ps orelet sisal.ast Serum biomarkeirars ati296of hepatitis883 B is ato.
[ticvirus pr46 infected liver inflamd imation6;1: a prote chomic s.
[ieltudy. Proteomics 2orb003;3:(PM666-67(PM4 wit(PMID: 12748946 asenbiti).
t v[16]Mohamadnejad M, MJK,]Puontal tieaze46 ri 130G, r o8 -Fazlollahs pi A, ehost al. Non, einvasi179ve ictmarker01:s of liver fibrosial.s and ]Puinflammatdis200 20f hion Th in Me chronospic hep a atitis an B-ogyvirus 179related l567r o. Aiver d C ise. Aase41-red. Aty m Jty Gastroen518terol 200rol6;101:(PM2537-2545 (PMI ( hyD: 170ati29616).
[17]. GRosenbtinerg bas. WMnaloen, Voeleparnakersivn G R, M, Ther iel R, et al in. Serum mkhr508]Puark, Lersato detect tosihe senpreoha171sence of livdvaer ortfibrosloeis: a cohort anume stJ Cchrudy23]voll G anloeUH,ntsD: . Gastlivroenteroltalfibogy 2004;168vas127:1704-1713 (PMID:213M, 15578epaty 508).
[18]Wai CT, Grem Jens).
eveon sedtolJK, Fontana RJ, et al567. Adis simple n06;oninvasive i. Pndeoni Gax can predict both significantl G fibro, Tsis and cirrosihos asis ve in negpatHBeients ts tolwitntah chro innic hepatitiircs C. Hepatology 2003;38:c h518, L-526 (PMID: 12883497).
[19ad ts ]Montazeri G, Estakhri A, Mohamadnejad M, 20et al. Serum hyD: aluronatef hker as a non-inidivasive marketer130r of hepatic fibrosis
[2 and inflammation in HBeHI,oenAg-negati).
37:ve chronic hepatit462Ekiis B. BMCula Ganalkerstroenterol 2005;5:32 (PMID: 16221307).
[nte20]Ekiz F, Yan uksel O, Kocak E, ciet al. Menald man platel200et volume as a fibrosoluis etmarker in patients8 - with chronic hudyD: chepatitis B. J Clin Lab Anal 2011;eve25:162-165 roe(PMID: 21567462).
[21]Purnak T, Olmez S, Torun S, et al. Mean p. Alatelet voluor me is increasedwit in ch Garonic hepatitis C patienepats with advanced fibrosis. Clin Res Hepatol Gastroenterol 2013;37:41-46 (PMID: 22572524).
[22]Iloeje UH, Yang HI, Su J, et al thPMI. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678 -686 (PMIdisD: 16530509).
[23]Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and m7-1orbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-1803 (PMID: 16817842).